AbCellera Q1 revenue more than doubles, beats estimates

AbCellera Biologics

11/05/2026 21:14

Overview

US biotechnology firm's Q1 revenue more than doubled, beating analyst expectations

Company posted a narrower net loss compared to Q1 2025

AbCellera ended Q1 with $655 mln in available liquidity

Outlook

Company says it is focused on delivering data readouts for clinical programs in 2026

AbCellera plans to advance ABCL688 and ABCL386 into IND-enabling studies in 2026

Company says it will select at least one additional development candidate in 2026

Result Drivers

COST MANAGEMENT - Co reported lower SG&A expenses, contributing to a narrower net loss

Company press release: ID:nBw2J1Wr7a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$8.30 mln
$5.86 mln (8 Analysts)
Q1 Net Income
-$43.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Abcellera Biologics Inc is $10.00, about 90.8% above its May 8 closing price of $5.24

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)